Article Abstract

Translating L-2-HG to kidney cancer at the bench and bedside

Authors: Omran Abu Aboud, Robert H. Weiss


Since the discovery of the oncogene in the 1970s with much fanfare including a Nobel Prize to Bishop and Varmus in 1989, the concept of oncogenesis—and the role of the oncogene in this process—has been refined and greatly expanded. While we all thought at that point that we had the etiology of cancer all figured out, subsequent work has resulted in the identification of six “hallmarks” of this disease (1) which include the old concept of sustained proliferative signaling, but also include what in the 1970s would have been unthinkable: metabolic reprogramming (2). This latter phenomenon, which often utilizes the technique of non-targeted metabolomics analysis to identify such pathways, capitalizes on the need of a rapidly growing tumor for an abundance of biochemical materials, and is one of the more recent advances in understanding malignancy as well as a path to new therapies (3).